Jing Qing, Li Huiying, Roman Linda J, Martásek Pavel, Poulos Thomas L, Silverman Richard B
Department of Chemistry, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208-3113, USA; Department of Molecular Biosciences, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208-3113, USA; Chemistry of Life Processes Institute, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208-3113, USA; Center for Molecular Innovation and Drug Discovery, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208-3113, USA.
Department of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697, USA; Department of Pharmaceutical Chemistry, University of California, Irvine, CA 92697, USA; Department of Chemistry, University of California, Irvine, CA 92697, USA.
Bioorg Med Chem Lett. 2014 Sep 15;24(18):4504-4510. doi: 10.1016/j.bmcl.2014.07.079. Epub 2014 Aug 12.
To develop potent and selective nNOS inhibitors, a new series of double-headed molecules with chiral linkers that derive from natural amino acid derivatives have been designed and synthesized. The new structures integrate a thiophenecarboximidamide head with two types of chiral linkers, presenting easy synthesis and good inhibitory properties. Inhibitor (S)-9b exhibits a potency of 14.7 nM against nNOS and is 1134 and 322-fold more selective for nNOS over eNOS and iNOS, respectively. Crystal structures show that the additional binding between the aminomethyl moiety of 9b and propionate A on the heme and tetrahydrobiopterin (H4B) in nNOS, but not eNOS, contributes to its high selectivity. This work demonstrates the advantage of integrating known structures into structure optimization, and it should be possible to more readily develop compounds that incorporate bioavailability with these advanced features. Moreover, this integrative strategy is a general approach in new drug discovery.
为了开发高效且具选择性的nNOS抑制剂,设计并合成了一系列新的具有源自天然氨基酸衍生物的手性连接基的双头分子。新结构将噻吩甲脒头部与两种手性连接基整合在一起,具有合成简便和良好抑制性能的特点。抑制剂(S)-9b对nNOS的抑制效力为14.7 nM,对nNOS的选择性分别比对eNOS和iNOS高1134倍和322倍。晶体结构表明,9b的氨甲基部分与nNOS(而非eNOS)中血红素上的丙酸A和四氢生物蝶呤(H4B)之间的额外结合,促成了其高选择性。这项工作证明了将已知结构整合到结构优化中的优势,并且应该能够更轻松地开发出兼具生物利用度和这些先进特性的化合物。此外,这种整合策略是新药发现中的一种通用方法。